首页 > 最新文献

Jornal Brasileiro De Pneumologia最新文献

英文 中文
The role of the pulmonary function laboratory in the management of gastrointestinal and liver diseases. 肺功能实验室在胃肠道和肝脏疾病管理中的作用。
IF 2.9 4区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-13 DOI: 10.36416/1806-3756/e20240350
José Alberto Neder, Denis E O'Donnell, Danilo C Berton
{"title":"The role of the pulmonary function laboratory in the management of gastrointestinal and liver diseases.","authors":"José Alberto Neder, Denis E O'Donnell, Danilo C Berton","doi":"10.36416/1806-3756/e20240350","DOIUrl":"https://doi.org/10.36416/1806-3756/e20240350","url":null,"abstract":"","PeriodicalId":14845,"journal":{"name":"Jornal Brasileiro De Pneumologia","volume":"50 6","pages":"e20240350"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert perspectives on tuberculosis screening procedures for migrants. 专家对移民结核病筛查程序的看法。
IF 2.9 4区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-13 eCollection Date: 2025-01-01 DOI: 10.36416/1806-3756/e20240347
Marina Pinheiro, David N Moreira, Ana Aguiar, Raquel Duarte

Objective: To evaluate the perspectives of tuberculosis experts from different countries regarding national screening procedures.

Methods: This was a qualitative descriptive study. Data were collected by using electronic, anonymized surveys with experts in tuberculosis in seven different countries within two World Health Organization regions (Europe and Africa). Thematic analysis was employed.

Results: The survey results indicate that there are varied perceptions of and experiences with national guidelines on screening for and treatment of tuberculosis (especially in the population tested), the appropriate timing of screening, types of tests, best practices, barriers, and limitations of the screening. The participants highlighted the importance of integrating health care services into the community to achieve people-centered health care. The study also sheds light on the importance of involving trained nurses and social workers in the screening process and of networks to ensure continuity of care.

Conclusions: The overall perceptions of the respondents underscore the importance of standardized screening guidelines. The ongoing collaboration between public health services, the private sector, and the community is essential to reduce tuberculosis transmission, as well as to provide substantial public health and economic benefits.

目的:评价不同国家结核病专家对国家筛查程序的看法。方法:定性描述性研究。数据是通过对世界卫生组织两个区域(欧洲和非洲)七个不同国家的结核病专家进行电子匿名调查收集的。采用专题分析。结果:调查结果表明,对于结核病筛查和治疗的国家准则(特别是在接受检测的人群中)、筛查的适当时机、检测类型、最佳做法、筛查的障碍和限制,人们的看法和经验各不相同。与会者强调了将卫生保健服务纳入社区以实现以人为本的卫生保健的重要性。该研究还阐明了让训练有素的护士和社会工作者参与筛查过程以及建立网络以确保护理连续性的重要性。结论:受访者的总体看法强调了标准化筛查指南的重要性。公共卫生服务、私营部门和社区之间的持续合作对于减少结核病的传播以及提供巨大的公共卫生和经济利益至关重要。
{"title":"Expert perspectives on tuberculosis screening procedures for migrants.","authors":"Marina Pinheiro, David N Moreira, Ana Aguiar, Raquel Duarte","doi":"10.36416/1806-3756/e20240347","DOIUrl":"https://doi.org/10.36416/1806-3756/e20240347","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the perspectives of tuberculosis experts from different countries regarding national screening procedures.</p><p><strong>Methods: </strong>This was a qualitative descriptive study. Data were collected by using electronic, anonymized surveys with experts in tuberculosis in seven different countries within two World Health Organization regions (Europe and Africa). Thematic analysis was employed.</p><p><strong>Results: </strong>The survey results indicate that there are varied perceptions of and experiences with national guidelines on screening for and treatment of tuberculosis (especially in the population tested), the appropriate timing of screening, types of tests, best practices, barriers, and limitations of the screening. The participants highlighted the importance of integrating health care services into the community to achieve people-centered health care. The study also sheds light on the importance of involving trained nurses and social workers in the screening process and of networks to ensure continuity of care.</p><p><strong>Conclusions: </strong>The overall perceptions of the respondents underscore the importance of standardized screening guidelines. The ongoing collaboration between public health services, the private sector, and the community is essential to reduce tuberculosis transmission, as well as to provide substantial public health and economic benefits.</p>","PeriodicalId":14845,"journal":{"name":"Jornal Brasileiro De Pneumologia","volume":"50 6","pages":"e20240347"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodal treatment of chronic thromboembolic pulmonary hypertension: initial experience at a university hospital in southern Brazil. 慢性血栓栓塞性肺动脉高压的多模式治疗:巴西南部一所大学医院的初步经验。
IF 2.9 4区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-13 DOI: 10.36416/1806-3756/e20240231
William Lorenzi, Rodrigo Vugman Wainstein, Roger Pirath Rodrigues, Igor Gorski Benedetto, Marcelo Basso Gazzana
{"title":"Multimodal treatment of chronic thromboembolic pulmonary hypertension: initial experience at a university hospital in southern Brazil.","authors":"William Lorenzi, Rodrigo Vugman Wainstein, Roger Pirath Rodrigues, Igor Gorski Benedetto, Marcelo Basso Gazzana","doi":"10.36416/1806-3756/e20240231","DOIUrl":"https://doi.org/10.36416/1806-3756/e20240231","url":null,"abstract":"","PeriodicalId":14845,"journal":{"name":"Jornal Brasileiro De Pneumologia","volume":"50 6","pages":"e20240231"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Silica-exposed patients with silicosis show shorter telomeres than do unexposed individuals: a pilot study in a population in southeastern Brazil. 二氧化硅暴露的矽肺病患者的端粒比未暴露的个体短:巴西东南部人群的一项初步研究。
IF 2.9 4区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-13 eCollection Date: 2025-01-01 DOI: 10.36416/1806-3756/e20240318
Marcos César Santos de Castro, Lucas de Carvalho Costa, Kaio Cezar Rodrigues Salum, Hermano Albuquerque de Castro, Patrícia Canto Ribeiro, Walter Costa, Angela Santos Ferreira Nani, Fabiana Barzotto Kohlrausch

Objective: Silicosis is a pneumoconiosis characterized by fibrosis of the lung parenchyma caused by the inhalation of silica particles. Silica dust inhalation is associated with inflammation and induction of oxidative stress in the lungs. This oxidative stress affects telomeres, which are short tandem DNA repeats that cap the end of linear chromosomes. We aimed to determine whether telomere length (TL) correlates with silicosis or severity of silicosis in silica-exposed workers in Brazil.

Methods: We included 200 men in southeastern Brazil: 100 with silicosis and 100 who had not been exposed to silica. We extracted DNA from buccal cells and assessed TL by multiplex quantitative polymerase chain reaction.

Results: The median TL was significantly shorter in the patients with silicosis than in the unexposed controls (p < 0.0001), although it did not differ between the patients with simple silicosis and those with complicated silicosis (p = 0.961). We also found that, in patients with silicosis, TL was influenced by smoking (p = 0.034) and by a history of personal protective equipment use in the workplace (p = 0.002).

Conclusions: Silica exposure appears to have an impact on TL, which was found to be shorter in patients with silicosis than in unexposed controls. Further studies are needed in order to confirm the impact that oxidative stress caused by silica inhalation has on telomeres.

目的:矽肺是一种以吸入二氧化硅颗粒引起的肺实质纤维化为特征的尘肺病。吸入二氧化硅粉尘与肺部炎症和氧化应激诱导有关。这种氧化应激会影响端粒,端粒是位于线性染色体末端的短串联DNA重复序列。我们的目的是确定端粒长度(TL)是否与硅肺或硅肺的严重程度在巴西的硅暴露工人相关。方法:我们纳入了巴西东南部的200名男性:100名患有矽肺病,100名未接触过二氧化硅的男性。我们从口腔细胞中提取DNA,用多重定量聚合酶链反应评估TL。结果:矽肺病患者的中位生存期明显短于未暴露对照组(p < 0.0001),单纯性矽肺病患者与合并性矽肺病患者的中位生存期无显著差异(p = 0.961)。我们还发现,在矽肺患者中,TL受吸烟(p = 0.034)和工作场所个人防护装备使用史(p = 0.002)的影响。结论:二氧化硅暴露似乎对TL有影响,发现矽肺病患者的TL比未暴露的对照组短。为了确认二氧化硅吸入引起的氧化应激对端粒的影响,需要进一步的研究。
{"title":"Silica-exposed patients with silicosis show shorter telomeres than do unexposed individuals: a pilot study in a population in southeastern Brazil.","authors":"Marcos César Santos de Castro, Lucas de Carvalho Costa, Kaio Cezar Rodrigues Salum, Hermano Albuquerque de Castro, Patrícia Canto Ribeiro, Walter Costa, Angela Santos Ferreira Nani, Fabiana Barzotto Kohlrausch","doi":"10.36416/1806-3756/e20240318","DOIUrl":"https://doi.org/10.36416/1806-3756/e20240318","url":null,"abstract":"<p><strong>Objective: </strong>Silicosis is a pneumoconiosis characterized by fibrosis of the lung parenchyma caused by the inhalation of silica particles. Silica dust inhalation is associated with inflammation and induction of oxidative stress in the lungs. This oxidative stress affects telomeres, which are short tandem DNA repeats that cap the end of linear chromosomes. We aimed to determine whether telomere length (TL) correlates with silicosis or severity of silicosis in silica-exposed workers in Brazil.</p><p><strong>Methods: </strong>We included 200 men in southeastern Brazil: 100 with silicosis and 100 who had not been exposed to silica. We extracted DNA from buccal cells and assessed TL by multiplex quantitative polymerase chain reaction.</p><p><strong>Results: </strong>The median TL was significantly shorter in the patients with silicosis than in the unexposed controls (p < 0.0001), although it did not differ between the patients with simple silicosis and those with complicated silicosis (p = 0.961). We also found that, in patients with silicosis, TL was influenced by smoking (p = 0.034) and by a history of personal protective equipment use in the workplace (p = 0.002).</p><p><strong>Conclusions: </strong>Silica exposure appears to have an impact on TL, which was found to be shorter in patients with silicosis than in unexposed controls. Further studies are needed in order to confirm the impact that oxidative stress caused by silica inhalation has on telomeres.</p>","PeriodicalId":14845,"journal":{"name":"Jornal Brasileiro De Pneumologia","volume":"50 6","pages":"e20240318"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review. 贝达喹啉、普雷托马尼、利奈唑胺和莫西沙星(BPaLM)治疗多药或利福平耐药结核病:一项系统综述。
IF 2.9 4区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-13 eCollection Date: 2025-01-01 DOI: 10.36416/1806-3756/e20240295
Denise Rossato Silva, Flávia Fonseca Fernandes, Juliana Carvalho Ferreira, Wanderley Bernando, Margareth Maria Pretti Dalcolmo, Fernanda Dockhorn Costa Johansen, Fernanda Carvalho de Queiroz Mello

Objective: To evaluate the available evidence comparing the use of the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) regimen for 6 months with that of standard-of-care regimens for patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB).

Methods: This was a systematic review of clinical trials comparing the use of the BPaLM regimen with the standard of care in patients with MDR/RR-TB. The main outcome measure was an unfavorable endpoint (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, and recurrence), and secondary outcome measures included adverse events and serious adverse events. We searched the MEDLINE, EMBASE, Google Scholar, LILACS, and ClinicalTrials.gov databases, from their inception to January 31, 2024, with no limitation as to language or year of publication. The risk of bias was assessed by using the Cochrane risk-of-bias tool, and the quality of evidence was based on the Grading of Recommendations Assessment, Development and Evaluation approach.

Results: A total of 3,668 studies were retrieved; only one (a randomized clinical trial) met the inclusion criteria and was included. In patients with MDR/RR-TB, treatment with the BPaLM regimen, when compared with the standard of care, reduced the risk of an unfavorable outcome (composite, number needed to treat [NNT] = 7); early treatment discontinuation (NNT = 8); adverse events and discontinuation (NNT = 12); and serious adverse events (NNT = 5).

Conclusions: This systematic review of the use of BPaLM in patients with MDR/RR-TB, although it included only one study, showed that BPaLM is more effective than is the standard of care and has a better safety profile. That has major implications for guidelines on the treatment of MDR/RR-TB.

目的:评价贝达喹啉、普雷托马奈德、利奈唑胺和莫西沙星(BPaLM)治疗6个月与耐多药或利福平结核病(MDR/RR-TB)患者标准治疗方案的现有证据。方法:这是一项比较使用BPaLM方案与MDR/RR-TB患者标准护理的临床试验的系统综述。主要结局指标是不利终点(死亡、治疗失败、治疗停止、失去随访和复发的综合指标),次要结局指标包括不良事件和严重不良事件。我们检索了MEDLINE、EMBASE、谷歌Scholar、LILACS和ClinicalTrials.gov数据库,从它们成立到2024年1月31日,没有语言或出版年份的限制。偏倚风险采用Cochrane偏倚风险工具评估,证据质量采用分级推荐评估、发展和评价方法。结果:共检索到3,668项研究;只有一项(随机临床试验)符合纳入标准并被纳入。在MDR/RR-TB患者中,与标准治疗方案相比,BPaLM方案治疗降低了不良结果的风险(综合,需要治疗的人数[NNT] = 7);早期停药(NNT = 8);不良事件和停药(NNT = 12);结论:这篇关于BPaLM在MDR/RR-TB患者中使用的系统综述,虽然只包括一项研究,但表明BPaLM比标准治疗更有效,并且具有更好的安全性。这对耐多药/耐药结核病治疗指南具有重大影响。
{"title":"Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review.","authors":"Denise Rossato Silva, Flávia Fonseca Fernandes, Juliana Carvalho Ferreira, Wanderley Bernando, Margareth Maria Pretti Dalcolmo, Fernanda Dockhorn Costa Johansen, Fernanda Carvalho de Queiroz Mello","doi":"10.36416/1806-3756/e20240295","DOIUrl":"https://doi.org/10.36416/1806-3756/e20240295","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the available evidence comparing the use of the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) regimen for 6 months with that of standard-of-care regimens for patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB).</p><p><strong>Methods: </strong>This was a systematic review of clinical trials comparing the use of the BPaLM regimen with the standard of care in patients with MDR/RR-TB. The main outcome measure was an unfavorable endpoint (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, and recurrence), and secondary outcome measures included adverse events and serious adverse events. We searched the MEDLINE, EMBASE, Google Scholar, LILACS, and ClinicalTrials.gov databases, from their inception to January 31, 2024, with no limitation as to language or year of publication. The risk of bias was assessed by using the Cochrane risk-of-bias tool, and the quality of evidence was based on the Grading of Recommendations Assessment, Development and Evaluation approach.</p><p><strong>Results: </strong>A total of 3,668 studies were retrieved; only one (a randomized clinical trial) met the inclusion criteria and was included. In patients with MDR/RR-TB, treatment with the BPaLM regimen, when compared with the standard of care, reduced the risk of an unfavorable outcome (composite, number needed to treat [NNT] = 7); early treatment discontinuation (NNT = 8); adverse events and discontinuation (NNT = 12); and serious adverse events (NNT = 5).</p><p><strong>Conclusions: </strong>This systematic review of the use of BPaLM in patients with MDR/RR-TB, although it included only one study, showed that BPaLM is more effective than is the standard of care and has a better safety profile. That has major implications for guidelines on the treatment of MDR/RR-TB.</p>","PeriodicalId":14845,"journal":{"name":"Jornal Brasileiro De Pneumologia","volume":"50 6","pages":"e20240295"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary pulmonary Hodgkin lymphoma presenting as cavitary lung lesions. 原发性肺霍奇金淋巴瘤表现为肺腔病变。
IF 2.9 4区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-13 DOI: 10.36416/1806-3756/e20240338
Roberta Wartchow Machado, Felipe Welter Langer, Rodrigo Dos Santos Ferrari
{"title":"Primary pulmonary Hodgkin lymphoma presenting as cavitary lung lesions.","authors":"Roberta Wartchow Machado, Felipe Welter Langer, Rodrigo Dos Santos Ferrari","doi":"10.36416/1806-3756/e20240338","DOIUrl":"https://doi.org/10.36416/1806-3756/e20240338","url":null,"abstract":"","PeriodicalId":14845,"journal":{"name":"Jornal Brasileiro De Pneumologia","volume":"50 6","pages":"e20240338"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120). Durvalumab作为不可切除III期NSCLC放化疗患者的巩固治疗:来自巴西扩大准入项目的真实数据(LACOG 0120)。
IF 2.9 4区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-13 eCollection Date: 2025-01-01 DOI: 10.36416/1806-3756/e20240228
Mauro Zukin, Victor Gondim, Andrea Kazumi Shimada, Ellias Magalhães E Abreu Lima, Clarissa Mathias, Williams Fernandes Barra, William Nassib William Junior, Mônica Padoan, Yuri Bittencourt, Rosely Yamamura, Carlos Eduardo Baston Silva, Letícia de Jesus Rossato, Caio de Almeida Monteiro, Rafaela Gomes de Jesus, Gustavo Gössling, Ana Caroline Zimmer Gelatti

Objective: The PACIFIC trial established standard therapy for patients with unresectable stage III NSCLC who did not progress after platinum-based concurrent chemoradiation therapy. However, real-world data, particularly from Latin America, remain limited. The LACOG 0120 study aimed to evaluate the efficacy and safety of consolidation therapy with durvalumab in a real-world setting in Brazil.

Methods: Patients with unresectable stage III NSCLC who received chemoradiotherapy followed by durvalumab consolidation therapy through an expanded access program were evaluated. The primary objective was to assess progression-free survival (PFS). Secondary endpoints included overall survival (OS), treatment compliance, and safety, with a focus on the incidence and severity of immune-mediated adverse events (NCT04948411).

Results: Thirty-one patients from seven centers were evaluated. Median follow-up was 50.3 months (95% CI: 48.6-54.4). Median PFS was 9.9 months (95% CI: 7.3-52.4), with a 36 month-PFS of 34.5% (95% CI: 17.7-52.1). Median OS was 34.9 months (95% CI: 26.0-NR), and the 36 month-OS was 46.3% (95% CI: 25.7-64.6). Durvalumab was administered for a median of 17 cycles (10 to 24), with 45.2% of patients completing the planned therapy. The main reason for discontinuation was disease progression. Treatment-related adverse events of any grade occurred in 12 patients (38.7%), with grade 3 events reported in two (6.5%). Pneumonitis was observed in 4 patients (12.9%) - grade 3 in 1 patient.

Conclusions: PFS was lower in this analysis compared to the PACIFIC trial; however, OS was similar, indicating comparable efficacy in a real-world setting among Brazilian patients with unresectable stage III NSCLC. No new safety concerns were identified.

目的:PACIFIC试验为无法切除的III期NSCLC患者建立了标准治疗方法,这些患者在铂基同步放化疗后没有进展。然而,真实世界的数据,特别是来自拉丁美洲的数据仍然有限。LACOG 0120研究旨在评估在巴西现实环境中durvalumab巩固治疗的有效性和安全性。方法:对无法切除的III期NSCLC患者进行评估,这些患者通过扩大准入计划接受放化疗和durvalumab巩固治疗。主要目的是评估无进展生存期(PFS)。次要终点包括总生存期(OS)、治疗依从性和安全性,重点是免疫介导的不良事件的发生率和严重程度(NCT04948411)。结果:对来自7个中心的31例患者进行了评估。中位随访为50.3个月(95% CI: 48.6-54.4)。中位PFS为9.9个月(95% CI: 7.3-52.4), 36个月PFS为34.5% (95% CI: 17.7-52.1)。中位OS为34.9个月(95% CI: 26.0-NR), 36个月OS为46.3% (95% CI: 25.7-64.6)。Durvalumab的中位用药周期为17个周期(10 - 24个周期),45.2%的患者完成了计划治疗。停药的主要原因是疾病进展。12名患者(38.7%)发生了任何级别的治疗相关不良事件,2名患者(6.5%)报告了3级不良事件。肺炎4例(12.9%),3级1例。结论:与PACIFIC试验相比,该分析的PFS较低;然而,OS是相似的,表明在现实环境中,巴西无法切除的III期NSCLC患者的疗效相当。没有发现新的安全隐患。
{"title":"Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120).","authors":"Mauro Zukin, Victor Gondim, Andrea Kazumi Shimada, Ellias Magalhães E Abreu Lima, Clarissa Mathias, Williams Fernandes Barra, William Nassib William Junior, Mônica Padoan, Yuri Bittencourt, Rosely Yamamura, Carlos Eduardo Baston Silva, Letícia de Jesus Rossato, Caio de Almeida Monteiro, Rafaela Gomes de Jesus, Gustavo Gössling, Ana Caroline Zimmer Gelatti","doi":"10.36416/1806-3756/e20240228","DOIUrl":"https://doi.org/10.36416/1806-3756/e20240228","url":null,"abstract":"<p><strong>Objective: </strong>The PACIFIC trial established standard therapy for patients with unresectable stage III NSCLC who did not progress after platinum-based concurrent chemoradiation therapy. However, real-world data, particularly from Latin America, remain limited. The LACOG 0120 study aimed to evaluate the efficacy and safety of consolidation therapy with durvalumab in a real-world setting in Brazil.</p><p><strong>Methods: </strong>Patients with unresectable stage III NSCLC who received chemoradiotherapy followed by durvalumab consolidation therapy through an expanded access program were evaluated. The primary objective was to assess progression-free survival (PFS). Secondary endpoints included overall survival (OS), treatment compliance, and safety, with a focus on the incidence and severity of immune-mediated adverse events (NCT04948411).</p><p><strong>Results: </strong>Thirty-one patients from seven centers were evaluated. Median follow-up was 50.3 months (95% CI: 48.6-54.4). Median PFS was 9.9 months (95% CI: 7.3-52.4), with a 36 month-PFS of 34.5% (95% CI: 17.7-52.1). Median OS was 34.9 months (95% CI: 26.0-NR), and the 36 month-OS was 46.3% (95% CI: 25.7-64.6). Durvalumab was administered for a median of 17 cycles (10 to 24), with 45.2% of patients completing the planned therapy. The main reason for discontinuation was disease progression. Treatment-related adverse events of any grade occurred in 12 patients (38.7%), with grade 3 events reported in two (6.5%). Pneumonitis was observed in 4 patients (12.9%) - grade 3 in 1 patient.</p><p><strong>Conclusions: </strong>PFS was lower in this analysis compared to the PACIFIC trial; however, OS was similar, indicating comparable efficacy in a real-world setting among Brazilian patients with unresectable stage III NSCLC. No new safety concerns were identified.</p>","PeriodicalId":14845,"journal":{"name":"Jornal Brasileiro De Pneumologia","volume":"50 6","pages":"e20240228"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perceptions and experiences of directly observed treatment in tuberculosis: insights from a mixed-methods cross-sectional study. 结核病直接观察治疗的认知和经验:来自混合方法横断面研究的见解。
IF 2.9 4区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-13 eCollection Date: 2025-01-01 DOI: 10.36416/1806-3756/e20240357
Diana Amorim, João Pedro Ramos, Pedro Barbosa, Mariana Vieira, Raquel Duarte

Objective: The demanding nature and psychosocial burdens of directly observed treatment (DOT) have opened a path to alternative strategies such as video-observed therapy (VOT), which offers comparable treatment outcomes and patient satisfaction while potentially saving time and reducing costs. The objective of this study was to evaluate the perceptions and experiences of patients and health care professionals regarding DOT and other treatment strategies implemented in Portugal.

Methods: Patients with a confirmed diagnosis of tuberculosis, treated at the Vila Nova de Gaia Outpatient Tuberculosis Centre in the last two years, were asked to complete a brief questionnaire, as were health care professionals working in the northern region of Portugal. Differences were analysed with chi-square tests, complemented by thematic analysis.

Results: A total of 62 individuals completed the questionnaire: 29 health care professionals and 33 patients. There were significant differences between the two groups in their views regarding the impact of DOT on treatment outcomes, with health care professionals perceiving a higher degree of negative effects and patients expressing greater satisfaction. Long travel distances, transportation issues and high costs were some of the challenges mentioned by the patients. Significant differences were also found regarding the role DOT plays in ensuring treatment adherence, with patients emphasising personal responsibility and its importance in preventing loss to follow-up and strengthening relationships with health care professionals. Dose dispensing was favoured for its convenience in specific situations, and VOT was generally preferred to reduce constant travelling. Both parties raised some concerns.

Conclusions: Existing discrepancies suggest a misalignment between patient experiences and health care provider perceptions, underscoring the need for enhanced communication and a more nuanced understanding of patient perspectives when designing and implementing different tuberculosis treatment adherence strategies.

目的:直接观察治疗(DOT)的苛刻性质和心理社会负担为视频观察治疗(VOT)等替代策略开辟了一条道路,视频观察治疗提供了类似的治疗结果和患者满意度,同时可能节省时间和降低成本。本研究的目的是评估患者和卫生保健专业人员对葡萄牙实施的DOT和其他治疗策略的看法和经验。方法:在过去两年中在加亚新城结核病门诊中心接受治疗的确诊结核病患者,以及在葡萄牙北部地区工作的卫生保健专业人员,被要求填写一份简短的调查问卷。差异分析采用卡方检验,辅以专题分析。结果:共62人完成问卷:29名医护人员和33名患者。两组在DOT对治疗结果影响的看法上存在显著差异,卫生保健专业人员感知到更高程度的负面影响,而患者表示更高程度的满意度。长途旅行、交通问题和高费用是患者提到的一些挑战。在DOT在确保治疗依从性方面发挥的作用方面也存在显著差异,患者强调个人责任及其在防止随访损失和加强与保健专业人员关系方面的重要性。配药因其在特定情况下的方便而受到青睐,而VOT一般更倾向于减少恒定的旅行。双方都提出了一些担忧。结论:现有的差异表明患者经验与卫生保健提供者的看法不一致,强调在设计和实施不同的结核病治疗依从性策略时需要加强沟通,更细致地了解患者的观点。
{"title":"Perceptions and experiences of directly observed treatment in tuberculosis: insights from a mixed-methods cross-sectional study.","authors":"Diana Amorim, João Pedro Ramos, Pedro Barbosa, Mariana Vieira, Raquel Duarte","doi":"10.36416/1806-3756/e20240357","DOIUrl":"https://doi.org/10.36416/1806-3756/e20240357","url":null,"abstract":"<p><strong>Objective: </strong>The demanding nature and psychosocial burdens of directly observed treatment (DOT) have opened a path to alternative strategies such as video-observed therapy (VOT), which offers comparable treatment outcomes and patient satisfaction while potentially saving time and reducing costs. The objective of this study was to evaluate the perceptions and experiences of patients and health care professionals regarding DOT and other treatment strategies implemented in Portugal.</p><p><strong>Methods: </strong>Patients with a confirmed diagnosis of tuberculosis, treated at the Vila Nova de Gaia Outpatient Tuberculosis Centre in the last two years, were asked to complete a brief questionnaire, as were health care professionals working in the northern region of Portugal. Differences were analysed with chi-square tests, complemented by thematic analysis.</p><p><strong>Results: </strong>A total of 62 individuals completed the questionnaire: 29 health care professionals and 33 patients. There were significant differences between the two groups in their views regarding the impact of DOT on treatment outcomes, with health care professionals perceiving a higher degree of negative effects and patients expressing greater satisfaction. Long travel distances, transportation issues and high costs were some of the challenges mentioned by the patients. Significant differences were also found regarding the role DOT plays in ensuring treatment adherence, with patients emphasising personal responsibility and its importance in preventing loss to follow-up and strengthening relationships with health care professionals. Dose dispensing was favoured for its convenience in specific situations, and VOT was generally preferred to reduce constant travelling. Both parties raised some concerns.</p><p><strong>Conclusions: </strong>Existing discrepancies suggest a misalignment between patient experiences and health care provider perceptions, underscoring the need for enhanced communication and a more nuanced understanding of patient perspectives when designing and implementing different tuberculosis treatment adherence strategies.</p>","PeriodicalId":14845,"journal":{"name":"Jornal Brasileiro De Pneumologia","volume":"50 6","pages":"e20240357"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: short- and long-term results from a cohort in Brazil. 球囊肺血管成形术治疗慢性血栓栓塞性肺动脉高压患者:来自巴西队列的短期和长期结果
IF 2.9 4区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-13 eCollection Date: 2025-01-01 DOI: 10.36416/1806-3756/e20240147
Fabio Solano de Freitas Souza, Marcelo Gottschald Ferreira, Iury Andrade Melo, Marta Ferreira Leite de Sá, Camila Melo Coelho Loureiro, Rosalvo Abreu, Paulo Henrique Alves de Carvalho, Mateus Dos Santos Viana, Valdemar Oliveira, Luiz Eduardo Fonteles Ritt

Objective: A significant number of patients with chronic thromboembolic pulmonary hypertension (CTEPH) are not eligible for pulmonary endarterectomy and may be treated with balloon pulmonary angioplasty (BPA). Although BPA programs have recently been developed in Brazil, no results have yet been published. The objective of this study was to assess the clinical and hemodynamic progression of the first patients treated with BPA at our center.

Methods: This was an observational study of 23 patients with CTEPH enrolled in the BPA program of a specialized center in Brazil between 2015 and 2020.

Results: After a mean of 5.6 ± 1.3 sessions and 11 ± 2.8 treated segments/patient (at a mean of 6.7 ± 2.9 months post-BPA), there was a 26% decrease in mean pulmonary artery pressure (51 ± 11 vs. 38 ± 11 mmHg; p < 0.0001), a 43% decrease in pulmonary vascular resistance (10 ± 3.7 vs. 5.7 ± 3.3 WU; p < 0.0001), and a 22.5% increase in the cardiac index (2.38 ± 0.6 vs. 2.95 ± 0.6 L/min/m2; p < 0.0001). There was an increase in the six-minute walk distance and an improvement in functional class. Acute lung injury with clinical manifestations was observed after 7% of the BPA sessions. None of the patients required intubation. During a mean outpatient follow-up period of 38 ± 22 months, two patients were referred for additional BPA sessions due to clinical worsening and new hospitalizations. Two deaths were recorded (due to CTEPH progression and gastrointestinal bleeding, respectively).

Conclusions: Among this first group of patients treated with BPA in Brazil, there was significant short- and long-term clinical improvement, together with a low frequency of complications.

目的:大量慢性血栓栓塞性肺动脉高压(CTEPH)患者不适合肺动脉内膜切除术,可采用球囊肺血管成形术(BPA)治疗。尽管BPA项目最近在巴西开展,但尚未公布任何结果。本研究的目的是评估本中心第一批接受双酚a治疗的患者的临床和血流动力学进展。方法:这是一项观察性研究,纳入了2015年至2020年间巴西一家专业中心BPA项目的23例CTEPH患者。结果:在平均5.6±1.3个疗程和11±2.8个治疗节段/患者后(bpa后平均6.7±2.9个月),平均肺动脉压下降26%(51±11比38±11 mmHg;p < 0.0001),肺血管阻力降低43%(10±3.7 vs 5.7±3.3 WU;p < 0.0001),心脏指数增加22.5%(2.38±0.6 vs. 2.95±0.6 L/min/m2;P < 0.0001)。6分钟的步行距离增加了,功能课程也有所改善。有7%的双酚a疗程后出现急性肺损伤,并有临床表现。没有患者需要插管。在平均38±22个月的门诊随访期间,2例患者因临床恶化和新住院而被转介进行额外的BPA治疗。记录了2例死亡(分别因CTEPH进展和胃肠道出血)。结论:在巴西接受BPA治疗的第一组患者中,有显著的短期和长期临床改善,并发症发生率低。
{"title":"Balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: short- and long-term results from a cohort in Brazil.","authors":"Fabio Solano de Freitas Souza, Marcelo Gottschald Ferreira, Iury Andrade Melo, Marta Ferreira Leite de Sá, Camila Melo Coelho Loureiro, Rosalvo Abreu, Paulo Henrique Alves de Carvalho, Mateus Dos Santos Viana, Valdemar Oliveira, Luiz Eduardo Fonteles Ritt","doi":"10.36416/1806-3756/e20240147","DOIUrl":"https://doi.org/10.36416/1806-3756/e20240147","url":null,"abstract":"<p><strong>Objective: </strong>A significant number of patients with chronic thromboembolic pulmonary hypertension (CTEPH) are not eligible for pulmonary endarterectomy and may be treated with balloon pulmonary angioplasty (BPA). Although BPA programs have recently been developed in Brazil, no results have yet been published. The objective of this study was to assess the clinical and hemodynamic progression of the first patients treated with BPA at our center.</p><p><strong>Methods: </strong>This was an observational study of 23 patients with CTEPH enrolled in the BPA program of a specialized center in Brazil between 2015 and 2020.</p><p><strong>Results: </strong>After a mean of 5.6 ± 1.3 sessions and 11 ± 2.8 treated segments/patient (at a mean of 6.7 ± 2.9 months post-BPA), there was a 26% decrease in mean pulmonary artery pressure (51 ± 11 vs. 38 ± 11 mmHg; p < 0.0001), a 43% decrease in pulmonary vascular resistance (10 ± 3.7 vs. 5.7 ± 3.3 WU; p < 0.0001), and a 22.5% increase in the cardiac index (2.38 ± 0.6 vs. 2.95 ± 0.6 L/min/m2; p < 0.0001). There was an increase in the six-minute walk distance and an improvement in functional class. Acute lung injury with clinical manifestations was observed after 7% of the BPA sessions. None of the patients required intubation. During a mean outpatient follow-up period of 38 ± 22 months, two patients were referred for additional BPA sessions due to clinical worsening and new hospitalizations. Two deaths were recorded (due to CTEPH progression and gastrointestinal bleeding, respectively).</p><p><strong>Conclusions: </strong>Among this first group of patients treated with BPA in Brazil, there was significant short- and long-term clinical improvement, together with a low frequency of complications.</p>","PeriodicalId":14845,"journal":{"name":"Jornal Brasileiro De Pneumologia","volume":"50 6","pages":"e20240147"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of segmentectomy versus lobectomy in adults with non-cystic fibrosis bronchiectasis. 成人非囊性纤维化支气管扩张的节段切除术与肺叶切除术的结果。
IF 2.9 4区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-13 eCollection Date: 2025-01-01 DOI: 10.36416/1806-3756/e20240301
José de Sá Moraes Neto, Isabele Alves Chirichela, Alessandro Wasum Mariani, Ricardo Mingarini Terra, Paulo Manuel Pêgo Fernandes

Objective: Surgical resection remains the gold standard treatment for bronchiectasis in patients who present with hemoptysis or suppuration, as well as in those who do not respond to clinical treatment. We sought to investigate the efficacy of sublobar resection (segmentectomy) and compare it with that of lobar resection (lobectomy) in patients with non-cystic fibrosis bronchiectasis.

Methods: Patients undergoing lobectomy or segmentectomy between 2019 and 2023 were included in the study. We analyzed intraoperative complications and postoperative outcomes, including length of hospital stay, length of ICU stay, and disease recurrence.

Results: There was no significant difference between the lobectomy and segmentectomy groups regarding the occurrence of intraoperative complications such as bleeding > 1000 ml, cardiogenic shock, and ventilatory instability (p > 0.999). However, the frequency of complications was significantly lower in the segmentectomy group than in the lobectomy group (p = 0.016). Hospital stays were longer in the lobectomy group than in the segmentectomy group (16 days vs. 5 days; p = 0.027), as were ICU stays (7 days vs. 1 day; p = 0.006). There was no significant difference between the lobectomy and segmentectomy groups regarding the recurrence rate (p = 0.541).

Conclusions: Early identification of bronchiectasis patients who are candidates for surgical resection is essential because those who are identified as such early on are candidates for parenchyma-sparing resections, which are similar to lobar resections in terms of disease control and lead to shorter hospital stays and better postoperative outcomes.

目的:对于出现咯血或化脓的支气管扩张患者,以及对临床治疗无效的患者,手术切除仍然是金标准治疗方法。我们试图探讨肺叶下切除术(节段切除术)的疗效,并将其与肺叶切除术(肺叶切除术)在非囊性纤维化支气管扩张患者中的疗效进行比较。方法:纳入2019 - 2023年间接受肺叶切除术或节段切除术的患者。我们分析术中并发症和术后结果,包括住院时间、ICU住院时间和疾病复发。结果:肺叶切除术组与节段切除术组术中出血> 1000 ml、心源性休克、通气不稳定等并发症的发生差异无统计学意义(p > 0.999)。然而,并发症发生率在节段切除术组明显低于肺叶切除术组(p = 0.016)。肺叶切除术组住院时间长于节段切除术组(16天比5天;p = 0.027), ICU住院时间(7天vs 1天;P = 0.006)。肺叶切除术组与节段切除术组复发率差异无统计学意义(p = 0.541)。结论:早期识别适合手术切除的支气管扩张患者至关重要,因为早期识别的患者可以选择保留实质的切除,这与疾病控制方面的大叶切除相似,可以缩短住院时间和改善术后效果。
{"title":"Outcomes of segmentectomy versus lobectomy in adults with non-cystic fibrosis bronchiectasis.","authors":"José de Sá Moraes Neto, Isabele Alves Chirichela, Alessandro Wasum Mariani, Ricardo Mingarini Terra, Paulo Manuel Pêgo Fernandes","doi":"10.36416/1806-3756/e20240301","DOIUrl":"https://doi.org/10.36416/1806-3756/e20240301","url":null,"abstract":"<p><strong>Objective: </strong>Surgical resection remains the gold standard treatment for bronchiectasis in patients who present with hemoptysis or suppuration, as well as in those who do not respond to clinical treatment. We sought to investigate the efficacy of sublobar resection (segmentectomy) and compare it with that of lobar resection (lobectomy) in patients with non-cystic fibrosis bronchiectasis.</p><p><strong>Methods: </strong>Patients undergoing lobectomy or segmentectomy between 2019 and 2023 were included in the study. We analyzed intraoperative complications and postoperative outcomes, including length of hospital stay, length of ICU stay, and disease recurrence.</p><p><strong>Results: </strong>There was no significant difference between the lobectomy and segmentectomy groups regarding the occurrence of intraoperative complications such as bleeding > 1000 ml, cardiogenic shock, and ventilatory instability (p > 0.999). However, the frequency of complications was significantly lower in the segmentectomy group than in the lobectomy group (p = 0.016). Hospital stays were longer in the lobectomy group than in the segmentectomy group (16 days vs. 5 days; p = 0.027), as were ICU stays (7 days vs. 1 day; p = 0.006). There was no significant difference between the lobectomy and segmentectomy groups regarding the recurrence rate (p = 0.541).</p><p><strong>Conclusions: </strong>Early identification of bronchiectasis patients who are candidates for surgical resection is essential because those who are identified as such early on are candidates for parenchyma-sparing resections, which are similar to lobar resections in terms of disease control and lead to shorter hospital stays and better postoperative outcomes.</p>","PeriodicalId":14845,"journal":{"name":"Jornal Brasileiro De Pneumologia","volume":"50 6","pages":"e20240301"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Jornal Brasileiro De Pneumologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1